ArticleUlusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES2026
Fraxin as a promising molecule in the pharmacological treatment of acute mesenteric ischemia: an experimental study.
Article in Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIschemia-reperfusion (I-R) injury associated with acute mesenteric vascular occlusion can lead to severe impairment of intestinal tissue and may become a life-threatening condition if not treated in the early clinical stages. Previous studies have suggested that fraxin may exert protective effects against I-R-induced mesenteric injury due to its antioxidant and anti-inflammatory properties.
methodsThis experimental study was conducted using healthy male Wistar albino rats. The animals were divided into four groups: a Sham group (superior mesenteric artery [SMA] isolated but not occluded), a Control group (SMA isolated and I-R induced), a 10 mg/kg Fraxin group, and a 50 mg/kg Fraxin group (fraxin administered before reperfusion). Total antioxidant status (TAS), total oxidant status (TOS), superoxide dismutase (SOD), glutathione peroxidase (GPx), and catalase (CAT) activities were evaluated. Histopathological examinations and inflammatory markers, including tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and myeloperoxidase (MPO), were also analyzed.
resultsIn the Sham group, SOD activity was 135.2±10.5 U/mg protein, GPx activity was 65.3±4.7 U/mg protein, and CAT activity was 85.1±5.8 U/mg protein. In the Control group, these values were 95.4±7.9, 45.7±3.6, and 60.3±4.2 U/mg protein, respectively. In 10 mg/kg Fraxin group, SOD, GPx, and CAT activities were 115.6±8.4, 55.8±4.2, and 75.6±5.5 U/mg protein, respectively; in the 50 mg/kg Fraxin group, the corresponding values were 130.8±9.7, 60.2±4.8, and 90.4±6.3 U/mg protein. Significant decreases in TNF-α, IL-6, and MPO levels were observed in the Fraxin-treated groups (p<0.05).
conclusionFraxin administration preserved tissues and improved antioxidant parameters by reducing oxidative stress and inflammation in the acute mesenteric artery ischemia-reperfusion injury (AMAIRI) model. Based on these findings, fraxin may be considered a potential therapeutic option for mesenteric ischemia-reperfusion-related injuries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.